Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2

  • Home
  • Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2

Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2

10, August 2021 |

Authors:

Sakib Nishat Islam Uddin Iqbal Hossen Ahmed Bashir Hossain Tohura Saif Jui Alam Islam Hasan Sufian Ali Islam Hossain Halim

Abstract


The receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein plays a vital role in binding and inter- nalization through the alpha-helix (AH) of human angiotensin-converting enzyme 2 (hACE2). Thus, it is a po- tential target for designing and developing antiviral agents. Inhibition of RBD activity of the S protein may be achieved by blocking RBD interaction with hACE2. In this context, inhibitors with large contact surface area are preferable as they can form a potentially stable complex with RBD of S protein and would not allow RBD to come in contact with hACE2. Peptides represent excellent features as potential anti-RBD agents due to better efficacy, safety, and tolerability in humans compared to that of small molecules. The present study has selected 645 antiviral peptides known to inhibit various viruses and computationally screened them against the RBD of SARS- CoV-2 S protein. In primary screening, 27 out of 645 peptides exhibited higher affinity for the RBD of S protein compared to that of AH of the hACE2 receptor. Subsequently, AVP1795 appeared as the most promising candidate that could inhibit hACE2 recognition by SARS-CoV 2 as was predicted by the molecular dynamics simulation. The critical residues in RBD found for protein-peptide interactions are TYR 489, GLY 485, TYR 505, and GLU 484. Peptide-protein interactions were substantially influenced by hydrogen bonding and hydrophobic interactions. This comprehensive computational screening may provide a guideline to design the most effective peptides targeting the spike protein, which could be studied further in vitro and in vivo for assessing their anti- SARS CoV-2 activity.